Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.71 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054287 | 0.80 | MAP2K1 (0.80) | MAP2K1 | |
| SCHEMBL6054308 | 0.79 | MAP2K1 (0.78) | MAP2K1 | |
| SCHEMBL3690176 | 0.79 | MAP2K1 (0.58) | MAP2K1SRC | |
| SCHEMBL3681877 | 0.79 | MAP2K1 (0.58) | MAP2K1SRC | |
| SCHEMBL3687662 | 0.78 | MAP2K1 (0.63) | MAP2K1 | |
| SCHEMBL13046479 | 0.77 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL3692710 | 0.77 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL3688790 | 0.77 | MAP2K1 (0.87) | MAP2K1 | |
| SCHEMBL13045211 | 0.77 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL3693390 | 0.76 | MAP2K1 (0.85) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578351-B1 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7030112-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050159420-A1 | Disruption of signal transduction by inhibition of kinases in target cells | SALVATI MARK (US) | 2005-07-21 | — | — | US | disclosed |
| US-6900208-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159420-A1 | Disruption of signal transduction by inhibition of kinases in target cells | MAP3K8, MAP3K5, MAP3K2 | MAP2K1 214/4885SRC 150/4885EGFR 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.